Epidarex Capital Research
Investment Thesis
Epidarex Capital is a transatlantic venture capital firm led by a diverse team of early-stage investors building breakthrough life science companies. The firm invests in early-stage, high-growth companies developing technologies with outstanding prospects for today's global healthcare market, and positions itself as a founding investor that transforms novel science into successful drugs and medical devices. Epidarex explicitly targets "emerging and under-ventured research hubs" within the UK and US, frequently partnering with leading universities and research institutions to spin out companies built around breakthrough academic science. The firm describes itself as a trusted partner to founders and co-investors, leveraging deep scientific and industry networks to build companies from formation through key value inflection points.
Sector Focus
Epidarex invests exclusively in life sciences and health technology, spanning:
- Therapeutics (small molecule and biologic drug development) across oncology, cardiometabolic, autoimmune, and neurological disease areas
- Medical devices (e.g., minimally invasive cardiovascular and neurovascular devices)
- Platform technologies with broad applicability across multiple disease areas
Investment criteria emphasize disruptive platform technologies addressing substantial unmet medical needs, novel innovations with sustainable competitive advantages, robust IP portfolios, clear regulatory/reimbursement strategies, and evidence of market validation and key opinion leader support.
Stage Focus
Epidarex targets seed and Series A rounds, typically acting as a founding investor in spinout companies emerging directly from academic institutions and research hubs. The firm's portfolio also shows selective follow-on participation into later rounds (e.g., RapidPulse's Series B) for companies it seeded early.
Check Size
The firm does not publish an explicit check-size range. Given its founding-investor, seed/Series A focus and a ~$145M Fund IV expected to back roughly 15 companies, typical initial commitments are consistent with life-science seed/Series A norms (single-digit millions), with reserves for follow-on participation in later rounds.
Lead Tendency
Epidarex explicitly positions itself to "lead early-stage financings, bridging the equity funding gap to build globally leading companies at scale," consistent with its founding-investor model. It also participates as a non-lead co-investor in some later-stage follow-on rounds (e.g., RapidPulse Series B, co-led by Medtronic, TechWald Next, and S3 Ventures).
Recent Activity
Epidarex closed the first tranche of Epidarex Capital IV, LP on January 27, 2026, securing over $145 million in commitments from investors including the British Business Bank, Strathclyde Pension Fund, the Scottish National Investment Bank, and family offices/corporates. Fund IV is expected to invest in up to 15 companies focused on oncology, cardiometabolic, autoimmune, and neurological conditions. On July 22, 2026, the firm announced leadership transitions tied to the fund launch: Kyp Sirinakis moved from Co-founder to Founding Partner after 16+ years, Elizabeth Roper and Peter Finan were promoted to Managing Partner, and Anthony Voveris was promoted to CFO. Portfolio company RapidPulse closed an oversubscribed $48M Series B in July 2026 to advance its stroke aspiration technology, with Epidarex participating alongside new co-leads Medtronic, TechWald Next, and S3 Ventures.
Portfolio Highlights
Epidarex's roughly 28-company portfolio spans clinical-stage biotech, preclinical platforms, and medical devices. Notable exits include Apellis Pharmaceuticals (now public on NASDAQ, subject of a pending Biogen acquisition announced April 2026), Confluence Life Sciences (acquired 2017), Harpoon Medical (acquired 2017), and SIRAKOSS (acquired 2020). Active portfolio companies with recent clinical or corporate milestones include NodThera (NLRP3 inflammasome inhibitors, new CEO and CFO hires in 2026, cardiometabolic data presented mid-2026), RapidPulse (stroke aspiration device, $48M Series B), Enterprise Therapeutics (Phase 2 primary efficacy hit in cystic fibrosis), Theolytics (first patient dosed in a Phase 1 oncolytic virus trial), Leucid Bio (CAR-T therapies, ongoing Phase I/IIa trial and a new collaboration with Syenex), and Lario Therapeutics (precision epilepsy medicines, recent non-dilutive grant funding).
Team
- A. Sinclair Dunlop, Managing Partner
- Kyparissia Sirinakis, Founding Partner (formerly Co-founder; transitioned July 2026 after 16+ years with the firm)
- Elizabeth Roper, Ph.D., Managing Partner
- Peter Finan, Ph.D., Managing Partner
- Mary Canning, Ph.D., Partner
- Lori Krim Gough, Ph.D., Partner
- Henning Steinhagen, Ph.D., Venture Partner
- Anthony Voveris, Chief Financial Officer
- Matthew Miessau, Principal
- Victor Pong, Ph.D., Associate
- Melissa Lezameta, Ph.D., Senior Associate
- Bridget Harris, Director of Operations
- Sara McGeachy, Investor Relations Analyst
The firm also maintains an Advisory Board including William Sellers, MD; Jeani Delagardelle; William Burns; and Paul Sekhri.
Decision Process
Epidarex operates as a partnership; entrepreneurs submit business plans to [email protected] and the firm reviews and follows up internally if a submission aligns with its stated investment criteria. Given the multi-partner leadership structure (four Managing/Founding Partners plus additional Partners), investment decisions likely require partnership-level consensus rather than a solo GP model.
Founder Preferences
The firm explicitly seeks "highly driven and tenacious founders and entrepreneurs" building around disruptive platform technologies with strong IP and a credible regulatory/reimbursement path. Its founding-investor, academic-spinout model suggests a preference for scientist-founders and academic teams that Epidarex helps professionalize with experienced operating leadership.
Geographic Focus
Epidarex is explicitly transatlantic, concentrating on "emerging and under-ventured research hubs" in the UK and US. The firm maintains a US presence in Bethesda, Maryland and a UK presence in Edinburgh, Scotland, reflecting its origin backing life-science spinouts from UK and US research institutions outside the traditional Boston/Bay Area/London hubs.